Among these, the dual DNA‐PK/TOR kinase inhibitor CC‐115 (Mortensen et al, 2015), which targets ATM‐deficient cancer cells in vitro (Tsuji et al, 2017) showed promising response in phase I clinical trials. Here, PRKDC is linked to cancer.